Non-small cell lung cancer: current treatment and future advances
- PMID: 27413711
- PMCID: PMC4931124
- DOI: 10.21037/tlcr.2016.06.07
Non-small cell lung cancer: current treatment and future advances
Abstract
Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases. Risk factors for developing NSCLC have been identified, with cigarette smoking being a major factor along with other environmental and genetic risk factors. Depending on the staging of lung cancer, patients are eligible for certain treatments ranging from surgery to radiation to chemotherapy as well as _targeted therapy. With the advancement of genetics and biomarkers testing, specific mutations have been identified to better _target treatment for individual patients. This review discusses current treatments including surgery, chemotherapy, radiotherapy, and immunotherapy as well as how biomarker testing has helped improve survival in patients with NSCLC.
Keywords: Chemotherapy; immunotherapy; non-small cell lung cancer (NSCLC).
Conflict of interest statement
Similar articles
-
Multimodality therapy in the treatment of lung cancer.Semin Respir Crit Care Med. 2004;25 Suppl 1:3-10. doi: 10.1055/s-2004-829639. Semin Respir Crit Care Med. 2004. PMID: 16088515
-
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28. Clin Lung Cancer. 2018. PMID: 29153898 Review.
-
Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.Cancer Prev Control. 1997 Dec;1(5):366-78. Cancer Prev Control. 1997. PMID: 9765759
-
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879. JAMA Netw Open. 2019. PMID: 31290993 Free PMC article.
-
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058. JAMA. 2019. PMID: 31454018 Review.
Cited by
-
Prediction of benign and malignant ground glass pulmonary nodules based on multi-feature fusion of attention mechanism.Front Oncol. 2024 Oct 9;14:1447132. doi: 10.3389/fonc.2024.1447132. eCollection 2024. Front Oncol. 2024. PMID: 39445066 Free PMC article.
-
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.Ther Adv Med Oncol. 2021 Feb 15;13:1758835921992968. doi: 10.1177/1758835921992968. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33643442 Free PMC article. Review.
-
Identification of key genes associated with lung adenocarcinoma by bioinformatics analysis.Sci Prog. 2021 Jan-Mar;104(1):36850421997276. doi: 10.1177/0036850421997276. Sci Prog. 2021. PMID: 33661044 Free PMC article.
-
Global research and current trends on nanotherapy in lung cancer research: a bibliometric analysis of 20 years.Discov Oncol. 2024 Oct 9;15(1):539. doi: 10.1007/s12672-024-01332-2. Discov Oncol. 2024. PMID: 39384612 Free PMC article.
-
Antitumor activities of Aspiletrein A, a steroidal saponin from Aspidistra letreae, on non-small cell lung cancer cells.BMC Complement Med Ther. 2021 Mar 9;21(1):87. doi: 10.1186/s12906-021-03262-w. BMC Complement Med Ther. 2021. PMID: 33750378 Free PMC article.
References
-
- American Cancer Society. Cancer Facts and Figures 2015. Available online: http://www.cancer.org/acs/groups/content/@editorial/documents/document/a...
-
- National Cancer Institute. SEER Cancer Statistics Review, 1975-2011. Available online: http://seer.cancer.gov/csr/1975_2011/
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources